Tumor Board, Research

Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients

July 22, 2025 Comments Off on Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients
A modern, multi-story medical research center is illuminated at dusk, with large glass windows and well-lit interiors. The building is labeled “Houston Methodist Research Institute.” City lights are visible in the background.

The National Synovial Sarcoma Tumor Board, a dedicated multidisciplinary team committed to improving outcomes for individuals affected by synovial sarcoma, is pleased to announce the ongoing expansion of its membership. This growth reflects our steadfast dedication to fostering innovative treatment strategies and providing personalized care for more patients nationwide.

We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach. Recent additions include Duke Health in North Carolina, Johns Hopkins University in Maryland, and the University of Minnesota/Masonic Cancer Center in Minnesota. These new members, along with our existing institutions, greatly enhance our ability to develop and implement cutting-edge, individualized treatment plans.

“Our goal is to push the boundaries of current treatment approaches and offer hope to patients facing this challenging diagnosis,” said Nathan Imperiale, Chairman of the Synovial Sarcoma Foundation. “The new medical professionals bring valuable insights and experience, which will help us refine our strategies and reach more patients who can benefit from innovative therapies.”

The Tumor Board’s continued growth underscores the foundation’s commitment to leading advancements in synovial sarcoma treatment and ensuring that every patient receives expert, tailored care. If your doctor or care team is not currently participating, please share this information with them! The Synovial Sarcoma Tumor Board offers an incredible opportunity for medical professionals to collaborate with leading experts and provide the best possible care for their patients.

The current list of participating institutions includes:

  • Atrium Health
  • Augusta Oncology
  • Barnes-Jewish Hospital
  • CancerCare Manitoba
  • Cedars-Sinai
  • Children’s Hospital Colorado
  • Children’s Hospital Los Angeles
  • Children’s Hospital Medical Center of Akron
  • Children’s Hospital of Orange County
  • Children’s Hospital of Philadelphia
  • Cincinnati Children’s Hospital
  • City of Hope
  • Cleveland Clinic
  • Columbia
  • Dana-Farber/Harvard Cancer Center
  • Dell Children’s Medical Center of Central Texas
  • John Hopkins
  • Kaiser Permanente Northern California
  • Lucile Packard Children’s Hospital
  • Maine Health
  • Mayo AZ
  • Mayo Clinic
  • MD Anderson Cancer Center
  • MD Anderson in Phoenix
  • Memorial Sloan Kettering Cancer Center
  • Nationwide Children’s Hospital
  • Northwestern Medicine
  • NYU Langhorne
  • Penn Medicine
  • Roswell Park Comprehensive Cancer Center
  • Seattle Children’s Hospital
  • St Jude Children’s Research Hospital
  • Stanford
  • UC Davis
  • UC San Diego
  • UC Santa Cruz
  • UCLA Health
  • UCSF Benioff Children’s Hospital
  • University of Rochester
  • University of Alabama at Birmingham
  • University of Arkansas for Medical Sciences
  • University of Colorado
  • University of Miami
  • University of Utah Health / Primary Children’s Hospital
  • University of Washington
  • UT Southwestern / Simmons Cancer Center-Dallas
  • Valley Children’s Hospital
  • Vanderbilt

For more information about the Tumor Board and how it is working to transform synovial sarcoma treatment, please visit our website.

Related posts

A healthcare professional in blue scrubs holds the hand of a patient in bed, offering comfort and support in a bright, sunlit room.
Research, Rare Cancer

Research Highlights Importance of Patient-Centered Sarcoma Surveillance

May 22, 2026 Comments Off on Research Highlights Importance of Patient-Centered Sarcoma Surveillance

A 2022 study explored how sarcoma patients feel about long-term surveillance imaging after treatment, highlighting the emotional, financial, and practical challenges that can come with ongoing follow-up care. The study, led by Sarah C. Tepper, Anna K. Holten, Cara A. Cipriano, and colleagues evaluated patient concerns surrounding surveillance imaging through the “Sarcoma Surveillance Survey.” The […]

A stethoscope rests on printed charts and graphs with blue bars and lines, representing medical or healthcare statistics and data analysis.
Rare Cancer Funding, Latest News

North America Synovial Sarcoma Treatment Market Expected to Grow Through 2033

May 14, 2026 Comments Off on North America Synovial Sarcoma Treatment Market Expected to Grow Through 2033

New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]

Two doctors examine X-ray images of a human skull, one in profile and one facing forward, while discussing the results in a well-lit medical setting.
Education, Rare Cancer

Rare Cranial Synovial Sarcoma Case Highlights Importance of Accurate Diagnosis

May 11, 2026 Comments Off on Rare Cranial Synovial Sarcoma Case Highlights Importance of Accurate Diagnosis

Synovial sarcoma is a rare and aggressive soft tissue cancer that most often develops near the joints of the arms or legs. In very rare cases, however, it can appear in unusual locations — including the skull and brain region. A newly published case report describes a patient diagnosed with primary cranial synovial sarcoma who […]